At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 599 enrolled
Drug / intervention
LY2189265 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Open-Label, Parallel-Arm Study Comparing the Effect of Once-Weekly Dulaglutide With Once-Daily Liraglutide in Patients With Type 2 Diabetes (AWARD-6: Assessment of Weekly AdministRation of LY2189265 in Diabetes-6)
In Brief
A Phase 3 clinical trial evaluating LY2189265, Liraglutide, and 1 other intervention for Type 2 Diabetes. Completed, enrolled 599 participants across 57 sites in 10 countries.
Detailed Summary
The purpose of the study is to assess the benefits and risks of once-weekly dulaglutide compared to once-daily liraglutide in participants with type 2 diabetes who have inadequate glycemic control on metformin.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes
CountriesCzechia, Germany, Hungary, Mexico, Poland, Puerto Rico, Romania, Slovakia, Spain, United States
Collaborators--
Timeline
Phase 3CompletedFinished
20132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2012
First PostedJun 2012
Primary CompletionNov 2013
TodayJul 2026
First PostedJun 20, 2012
Enrollment StartJun 1, 2012
Primary CompletionNov 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 14.0 years ago
Interventions
LY2189265drug
Administered SC
Liraglutidedrug
Administered SC
Metformindrug